Bifurcación de tronco de coronaria distal: cantidad de stents

Bifurcation Lesion in Distal Left Main Coronary Artery: One or Two Stents?

Courtesy of Dr. Carlos Fava. Unprotected left main coronary artery (LMCA) angioplasty has become an important trend in the last few years.   One of the most significant unresolved questions about it is whether one stent is better than two in distal lesions, and how is their progress after treatment.   This study included 937 patients who<a href="https://solaci.org/en/2016/11/16/bifurcation-lesion-in-distal-left-main-coronary-artery-one-or-two-stents/" title="Read more" >...</a>

$Masa miocárdica fraccional para evaluar la severidad de la estenosis$

A New Indicator to Assess Stenosis Severity

This study looked at the role of fractional myocardial mass (vessel-specific myocardial mass) in the assessment of stenosis physiological severity.   Researchers used CT angiography to study this new concept of myocardial mass subtended by a specific vessel, which could reduce anatomical-physiological mismatch.   The study included 463 patients with 724 lesions evaluated by multislice<a href="https://solaci.org/en/2016/08/29/a-new-indicator-to-assess-stenosis-severity/" title="Read more" >...</a>

Visual Assessment and Misinterpretation of Coronary Lesion Severity

  Courtesy of Dr. Pablo Baglioni. The visual interpretation of coronary angiographies is still used to decide for or against revascularization of ambiguous coronary lesions. Multiple factors other than stenosis degree, have been associated with the functional significance of lesions. The aim of this study was to analyze the ability of interventionists to visually assess<a href="https://solaci.org/en/2016/07/26/visual-assessment-and-misinterpretation-of-coronary-lesion-severity/" title="Read more" >...</a>

Instent restenosis: Drug eluting balloons or drug eluting stents?

Original Title: Long-Term Results of Everolimus-Eluting Stents versus Drug-Eluting Balloons in Patients with Bare-Metal In-Stent Restenosis 3-Year Follow-Up of the RIBS V Clinical Trial. Reference: Alfonso F. et al. JACC Cardiovasc Interv. 2016 Jun 27;9(12):1246-55.   Courtesy of Dr. Agustín Vecchia.   RIBS V 3 year follow up Stents have become the gold standard for<a href="https://solaci.org/en/2016/06/28/instent-restenosis-drug-eluting-balloons-or-drug-eluting-stents/" title="Read more" >...</a>

FAVOR: Diagnostic Accuracy of FFR derived from coronary angiography, the QFR

Original Title: Diagnostic accuracy of a fast computational approach to derive FFR from coronary X-ray angiography: results from the international multicenter FAVOR (Functional Assessment by Varios flow Reconstruction) pilot study. Presenter: Shengxian Tu.   Pressure gradient across coronary stenosis is associated to flow and influenced by obstruction geometry. The QFR (quantitative flow ratio) is a<a href="https://solaci.org/en/2016/05/23/favor-diagnostic-accuracy-of-ffr-derived-from-coronary-angiography-the-qfr/" title="Read more" >...</a>

VELETI II: PCI to Intermediate coronary SVG lesions with DES

Original Title: Sealing intermediate non-obstructive coronary SVG lesions with DES as a new approach to maintaining vein graft patency and reducing cardiac events: the VELETI II randomized clinical trial. Presenter: J. Rodes Cabal.   Non-obstructive SVG lesions affect mid-term prognosis negatively. There is little evidence on the safety and efficacy of non-obstructive intermediate SVG lesions<a href="https://solaci.org/en/2016/05/20/veleti-ii-pci-to-intermediate-coronary-svg-lesions-with-des/" title="Read more" >...</a>

Long Term Outcomes of Routine vs. Provisional T-stenting for De Novo Coronary Bifurcations: Five Year Outcomes of the BBK-I Trial

Original Title: “Long-term outcomes of routine versus provisional T-stenting for de novo coronary bifurcation lesions: five-year results of the Bifurcations Bad Krozingen I study”. Authors: Miroslaw Ferenc, MD; Mohamed Ayoub, MD; Hans-Joachim Büttner, MD; Michael Gick, MD; Thomas Comberg, MD; Jürgen Rothe, MD; Christian M. Valina, MD; Willibald Hochholzer, MD; Franz-Josef Neumann, MD. Division of Cardiology and<a href="https://solaci.org/en/2015/12/28/long-term-outcomes-of-routine-vs-provisional-t-stenting-for-de-novo-coronary-bifurcations-five-year-outcomes-of-the-bbk-i-trial/" title="Read more" >...</a>

RIBS IV: Drug-eluting balloon versus everolimus-eluting stent on in-stent restenosis

This prospective, multicenter, randomized trial compared the paclitaxel-eluting balloon versus everolimus-eluting stent to treat patients with in-stent restenosis. 309 patients were included in total (154 received the drug-eluting balloon, and 155 received the everolimus-eluting stent). There were no differences in the characteristics of both groups. At one year the rate of cardiac death, myocardial infarction<a href="https://solaci.org/en/2015/06/24/ribs-iv-drug-eluting-balloon-versus-everolimus-eluting-stent-on-in-stent-restenosis/" title="Read more" >...</a>

BABILON: Pharmacological balloon to treat the lateral branch in coronary bifurcations

The paclitaxel-eluting balloon could be an option to minimize the side branch restenosis in coronary bifurcations. In this study, the angiographic and clinical outcomes of paclitaxel-eluting balloon plus conventional stent versus DES in bifurcation “de novo” lesion were compared.  This multicenter study included 108 patients randomized to sequential dilation of the main branch and the<a href="https://solaci.org/en/2015/06/24/babilon-pharmacological-balloon-to-treat-the-lateral-branch-in-coronary-bifurcations/" title="Read more" >...</a>

ISAR-DESIRE 3: A paclitaxel eluting balloon versus Taxus in the treatment of eluting stent restenosis.

Fundamentals. Background: Although we’ve had more than a decade of experience with implanting drug-eluting stents, (DES), the best treatment for restenosis on these devices remains unknown. The drug-eluting balloons are a promising alternative which avoid the possibility of a new layer of metal on the restenotic injury. This study compared the performance of these balls<a href="https://solaci.org/en/2015/06/24/isar-desire-3-a-paclitaxel-eluting-balloon-versus-taxus-in-the-treatment-of-eluting-stent-restenosis/" title="Read more" >...</a>